Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Other 2Sarcoma 1Gastrointestinal 1CNS 1Breast 1

Conditions

Osteoporosis 1Myocardial Ischemia 1Heart Diseases 1Coronary Disease 1Colonic Neoplasms 1Cardiovascular Diseases 1Breast Neoplasms 1Bone Diseases 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Progestins × Breast × Clear all
NCT00000611 2016-04-15

Women's Health Initiative (WHI)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
BreastGastrointestinal

Bone Diseases, Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Coronary Disease, Heart Diseases, Osteoporosis, Myocardial Ischemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡